The move follows the expiry of the patent for semaglutide in the country, with the launch coming on day one of patent expiry.
In a press release filed with the exchanges, Natco said the multi-dose vial format is priced around 70% lower than pen devices and nearly 90% cheaper than the innovator product, which is expected to improve patient access and long-term treatment adherence.
The drug will be made in multi-dose vial formats under the brand names SEMANAT and SEMAFULL, in strengths of 2 mg/1.5 ml, 4 mg/3 ml and 8 mg/3 ml.
Natco said it received approval from the Central Drugs Standard Control Organisation (CDSCO) in February
2026 to manufacture and market the product in India.
It also plans to launch a pen device version in April 2026, priced between ₹4,000 and ₹4,500 per month, depending on dosage.
Semaglutide is used in the treatment of type 2 diabetes as an adjunct to diet and exercise.
The company added that it is the first to offer generic semaglutide in a multi-dose vial format in India and will also make the product available for co-marketing partnerships.
Earlier this month, Natco, along with its partner Breckenridge Pharmaceutical, launched Pomalidomide capsules, a generic version of Pomalyst by Celgene, in the US market.
Following the announcement, shares of Natco Pharma gained 968.10 as of 11.31 am. The stock has delivered a 17.2% return over the last 12 months.
